📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (2024)

First Author: Nasir M

Attributed to: MRC Centre for Neuropsychiatric Genetics and Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.msard.2024.105528

Publication URI: http://dx.doi.org/10.1016/j.msard.2024.105528

Type: Journal Article/Review

Parent Publication: Multiple Sclerosis and Related Disorders